BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37339176)

  • 21. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
    Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
    Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
    Shu L; Wang D; Nannapaneni S; Sun Y; Griffith CC; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM; Chen ZG; Saba NF
    Oral Oncol; 2021 Nov; 122():105546. PubMed ID: 34700281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
    Jin N; Keam B; Cho J; Lee MJ; Kim HR; Torosyan H; Jura N; Ng PK; Mills GB; Li H; Zeng Y; Barbash Z; Tarcic G; Kang H; Bauman JE; Kim MO; VanLandingham NK; Swaney DL; Krogan NJ; Johnson DE; Grandis JR
    J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
    Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
    Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
    Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
    Hanna GJ; Guenette JP; Chau NG; Sayehli CM; Wilhelm C; Metcalf R; Wong DJ; Brose M; Razaq M; PĂ©rez-Ruiz E; Cohen EEW; Aggarwal R; Scholz C; Gualberto A; Ho AL
    Cancer; 2020 Sep; 126(17):3972-3981. PubMed ID: 32557577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn LA; Fury MG; Xiao H; Baxi SS; Sherman EJ; Korte S; Pfister C; Haque S; Katabi N; Ho AL; Pfister DG
    Ann Oncol; 2017 Oct; 28(10):2533-2538. PubMed ID: 28961834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?
    Ben Yahia H; Petit FM; Saada-Bouzid E
    Curr Opin Oncol; 2023 May; 35(3):178-185. PubMed ID: 36966498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.
    Desilets A; Ho AL
    Cancer J; 2022 Sep-Oct 01; 28(5):363-368. PubMed ID: 36165724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
    Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
    IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
    Swick AD; Prabakaran PJ; Miller MC; Javaid AM; Fisher MM; Sampene E; Ong IM; Hu R; Iida M; Nickel KP; Bruce JY; Wheeler DL; Kimple RJ
    Mol Cancer Ther; 2017 Jul; 16(7):1257-1268. PubMed ID: 28446642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.
    Yamaguchi K; Iglesias-Bartolomé R; Wang Z; Callejas-Valera JL; Amornphimoltham P; Molinolo AA; Cohen EE; Califano JA; Lippman SM; Luo J; Gutkind JS
    Oncotarget; 2016 Mar; 7(10):10696-709. PubMed ID: 26882569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
    Chen X; Cao Y; Sedhom W; Lu L; Liu Y; Wang H; Oka M; Bornstein S; Said S; Song J; Lu SL
    Mol Oncol; 2020 Jan; 14(1):139-158. PubMed ID: 31600013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
    Nichols AC; Black M; Yoo J; Pinto N; Fernandes A; Haibe-Kains B; Boutros PC; Barrett JW
    BMC Pharmacol Toxicol; 2014 Nov; 15():66. PubMed ID: 25428177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
    Geiger JL; Bauman JE; Gibson MK; Gooding WE; Varadarajan P; Kotsakis A; Martin D; Gutkind JS; Hedberg ML; Grandis JR; Argiris A
    Head Neck; 2016 Dec; 38(12):1759-1764. PubMed ID: 27232378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
    Madera D; Vitale-Cross L; Martin D; Schneider A; Molinolo AA; Gangane N; Carey TE; McHugh JB; Komarck CM; Walline HM; William WN; Seethala RR; Ferris RL; Gutkind JS
    Cancer Prev Res (Phila); 2015 Mar; 8(3):197-207. PubMed ID: 25681087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.